Pregnant Patients With Opioid Use Disorder Still Miss Gold-Standard Treatment, Study Finds

Why the number is so consequential

Pregnancy often brings more frequent contact with doctors, clinics, and hospitals than many people have at any other time in adulthood. That makes the low treatment rate especially striking. If fewer than half of diagnosed patients receive medication during this period, the implication is not merely that care is imperfect. It is that a major clinical intervention is still failing to reach a large share of the people for whom it is intended.

The study does not attempt to explain every reason for the shortfall, but the finding lands in the middle of a broader national debate over how addiction care is delivered in obstetrics. In practice, patients may face insurance hurdles, provider shortages, lack of integrated prenatal and addiction services, and fear of judgment or legal consequences. The paper itself stays focused on claims data and associations, but the overall message is difficult to miss: diagnosis alone does not ensure treatment.

That gap has consequences beyond a single prescription. Medication treatment can be part of a broader care plan that includes prenatal monitoring, behavioral health support, and postpartum follow-up. Without it, the clinical burden shifts back onto patients already navigating a demanding and medically sensitive period.

What the study adds

Large national estimates are useful because they move the conversation beyond anecdote. This analysis did not rely on a single hospital system or one state program. Instead, it drew from a nationwide commercial insurance database, giving a broader view of treatment patterns among insured patients.

At the same time, the dataset also sets limits on what can be concluded. The study reflects people with commercial insurance, not the entire pregnant population. It measures diagnosed opioid use disorder rather than all underlying cases, which means undiagnosed patients are outside the count. And while it identifies patterns associated with treatment receipt, it does not establish why any one patient did or did not receive medication.

Still, the main finding is robust enough to shape policy and practice discussions. If medication is the gold standard and fewer than half of diagnosed pregnant patients receive it, then improving access is not a marginal adjustment. It is a central unfinished task.

Where intervention may matter most

The study’s subgroup findings may help focus that work. Patients with chronic pain and those with additional substance use disorder diagnoses appeared less likely to receive MOUD during pregnancy. Those are populations that may require more coordinated treatment models, not fewer. Their lower treatment rates suggest the presence of clinical complexity may be acting as a barrier rather than a trigger for more comprehensive care.

Meanwhile, the positive association between multiple mental health disorders and treatment receipt could indicate that contact with behavioral health services improves the odds of receiving evidence-based addiction care. If so, one lesson is that integration matters. Systems that connect obstetrics, psychiatry, and addiction treatment may be better positioned to deliver appropriate care than siloed models in which each condition is handled separately.

The authors said their findings underscore the need for targeted interventions. That likely means practical changes: screening that leads directly to treatment pathways, more clinicians prepared to prescribe and manage MOUD in pregnancy, and care models designed for patients with overlapping pain, mental health, and substance use needs.

The study does not claim to solve those problems. But it makes the treatment gap harder to ignore. In a population where the standard of care is well established and the health stakes are unusually high, fewer than half receiving medication is a number that demands a response.

This article is based on reporting by Medical Xpress. Read the original article.